ClinicalTrials.gg
CompletedNCT06241976DELVEUpdated Mar 12, 2025

Diabetes Risk in London and Its Association with Vitamin D by Ethnic Group (DELVE)

An interventional study of Glucose drink and Pure orange juice in Hyperglycemia, Postprandial and Vitamin D Status, sponsored by City, University of London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by City, University of London · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Jul 2023, registered Nov 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of this study is to investigate the relationship between vitamin D status and a diabetes risk factor, postprandial glycaemic response in White, South Asian and Black African Caribbean populations in London.

The main question[s] it aims to answer are:

  • Are there differences in postprandial glycaemic response to a sugar water drink or orange juice between White, South Asian and Black African Caribbean people in London?
  • Is there a relationship plasma 25(OH)D and the postprandial glycaemic response to a sugar water drink or orange juice consumption?
  • What are the knowledge and perceptions of vitamin D intake between White, South Asian and Black African Caribbean people in London?
  • Is there a difference in dietary vitamin D intake between the three ethnic groups?

Participants will make two visits to the lab, approximately 2.5 hours each. The order of the two drinks will be randomized via Excel Random function. For each visit, the blood sugar levels will be measured at fasting (0) and every 30 minutes up to 2 hours postprandially (5 times total) using a finger prick. At baseline only (visit 1), participants will fill out a knowledge and perception survey, provide a 4-day estimated food diary, provide a 7 ml blood sample via phlebotomy, and have their height, weight and body fat percentage measured.

Read the detailed description

Background

Health patterns differ significantly between ethnic minority groups and the white population. In the United Kingdom (UK), the risk of developing diabetes is two-to-six times higher in South Asians (SAs) and up to three times higher in Black African-Caribbeans (ACs) than in white Caucasians and people in these groups develop the condition at a younger age. Parts of London are among the areas of the UK with the highest proportion of minority groups and highest prevalence of Type-2 Diabetes Mellitus (T2DM). Although multiple factors have been identified including socio-economic standing, diet, culture and attitude, language barriers, genetic, epi-genetic and lifestyles, research into biological diversity is much under-investigated. Recent research found that the postprandial glucose peak in SAs is two-three times larger than that in white Caucasians after identical carbohydrate loads. Our unpublished data also showed the postprandial glucose peak was significantly higher in non-white (Chinese, Indian and Black) than white participants (6.11 nmol/L vs 5.15 nmol/L, P=0.015) after white bread consumption. Though obesity is believed to account for 80-85% of the risk of developing T2DM due to obesity causing insulin resistance, and some minority groups e.g. the Black African and Caribbean population have a higher overweight and obesity prevalence than white Caucasians (73.6% vs. 63.3%), other biological mechanisms have been sparsely investigated, among which is vitamin D (vitD). VitD deficiency in minority groups in the UK is well known and is described as an unrecognized epidemic. In the UK, 50% of SAs and 33% of black ACs demonstrate vitD deficiency vs. 17.5% in white Caucasians, primarily due to more subcutaneous pigmentation that absorbs Ultraviolet B from the sunlight and reduces vitD production in the skin and high latitudes in the UK. This situation is worse in East London in particular because 47% of AC people and 42% of SA people had vitD deficiency compared with 17% of white population in Tower Hamlets. An inverse association of serum 25(OH)D levels with insulin resistance was observed in healthy adults and diabetic patients. Recent evidence shows vitD supplementation may help improve glycaemic control and insulin resistance in T2DM patients. However, little evidence is available for minority groups or residents in London, indicating London (particularly East London) AC and SA communities being underrepresented in the evidence base surrounding diabetes and vitamin D. VitD plays important roles in calcium metabolism and involves in modulation of cell growth, neuromuscular and immune function, and reduction of inflammation due to its receptors expressed ubiquitously in nearly all human cells including the pancreatic β-cells. Animal studies show vitD treatment improved insulin production and sensitivity, and the increased insulin secretion may be caused by a higher intracellular calcium. Moreover, 1, 25(OH)2D (the active form of vitD) may modulate β-cell growth and differentiation. The secondary high parathyroid hormone (PTH) concentration and increased inflammatory markers associated with vitD deficiency may also cause glucose intolerance. VitD may have indirect impact on glycaemic control via obesity. Our research and many others have shown a significant inverse association of body mass index (BMI) and serum 25(OH)D. This is thought to be due to a complex of mutual influence because vitD receptors are expressed on adipose cells and regulate their functions, indicating vitD deficiency might be one of the causes of obesity, thus indirectly leading to increased risk of T2DM.

Postprandial glycaemic response (PGR) has implications in T2DM development. The oral glucose tolerance test (OGTT) is widely used to assess the insulin sensitivity, the pancreatic β-cell function, and judge an individual's metabolic capacity to handle carbohydrate foods. However, a recently published study indicated that within- subject variations of the PGR pattern may exist between OGTT and food intake, suggesting a necessity of combining OGTT and a meal/drink tolerance test for individualized glycemic management. The awareness of vitD and its impact on health is poor in the UK. Though the COVID-19 pandemic has brought vitD to the public attention, a recent UK survey reveals that 49% adults are unaware of UK Government guidelines for vitamin D. There is no such survey available on the minority groups, nor in residents of London. The investigators are interested in the dietary vitamin D intake between different ethnic groups in London, which will be partly explanatory to vitD status in the target population and there is an urgent call for research on minority population to address health inequality.

Aims

To investigate the difference in postprandial glycemic response to oral glucose tolerance tests and orange juice consumption between white Caucasian, South Asian and Black African and Caribbean adults

To investigate the association of serum 25(OH)D concentration with postprandial glycemic response to oral glucose tolerance tests and orange juice consumption between white Caucasian, South Asian and Black African and Caribbean adults

To assess the knowledge and perception of vitamin D, and dietary vitamin D intake in white Caucasian, South Asian and Black African and Caribbean adults

Study design

This is an acute, randomized, repeated measures cross-over design study. 126 healthy adults living in London will be recruited from white Caucasian, South Asian and Black African and Caribbean populations (n=42 in each group).

Recruitment

Participants will be recruited in two ways:

  • From staff and students who live in London with gatekeeper permissions Recruitment adverts will be circulated to staff and students at City, University of London.
  • From local communities in London with gatekeeper permissions. More communities will be identified in London to help us with recruitment by circulating the project advert, e.g., East London Community College, East London Community Band, and various community centers in London. In addition, the advert leaflets will be posted at the local supermarkets, libraries, hairdressers and barbers, food outlets etc. with permission of gatekeepers.

Treatments

Participants will consume a glucose drink (75g glucose in 300 ml water, 281 kcal) used for oral glucose tolerance test (OGTT) and pure orange juice (OJ, 100% Pure Squeezed Orange Juice Smooth 300 ml containing 129 kcal, 30 g sugar, 0.3 g fibre, 1.8 g protein and 90 mg vitamin C) on separate occasions with at least 48-hour interval and in a random order. Participants are instructed to consumed each drink consumption within a 5 minute period (time taken is recorded). During the two hour study period, participants remain sedentary and cannot eat and drink anything additional.

Sample and data collection

On the night prior to each of their study visit, participants are asked to follow their normal dietary pattern, have a good night's sleep and avoid alcohol and intensive exercise. Participants are instructed to fast for at least eight hours prior to their visit start time.

Blood glucose concentration is measured at baseline (0 minutes), +30 minutes, +60 minutes, +90 minutes and 120 min by finger prick blood sampling and measured using the HemoCue glucose analyser (HemoCue Ltd, Angelholm, Sweden). For the first visit only, a 7-ml fasting blood is collected at baseline (0 minutes) via phlebotomy to measure serum 25(OH)D, C-reactive protein (CRP), parathyroid hormone (PTH), calcium, cholesterol and high-density lipoprotein (HDL). Body mass index (BMI) and fat composition will be measured using a stadiometer and bioelectric impendence analyzing scale (Tanita, Amsterdam). Participants will complete a vitamin D knowledge questionnaire (at baseline) that includes demographics questions including ethnicity. Dietary vitamin D intake is assessed through an estimated food diary that participants complete over four consecutive days (between visits 1 and 2).

Randomization

The order of the drink consumption is randomized by using Excel Random function. Details are below. In Excel spreadsheet, a list of participants (from 1-126) is shown in one column. On the next column, the RANDBETWEEN function is used, and choosing 0 and 1 as the range to randomly generate the value of 0 or 1. Participants with a value of 0 will consume glucose drink while participants with a value of 1 will consume pure orange juice as their first drink respectively.

Statistical analysis

This study aims to achieve a minimum of 25% variability in postprandial glycaemic response among three ethnic groups considering the response has taken from five different time points with 30 min interval for each person and to achieve an 90% power of the study, 42 people are required in each group (n=126 in total) at 5% level of significance. Continuous data will be presented as mean±standard deviation. Categorical data will be presented as percentage. A two-way repeated measures ANOVA is used to assess the treatment (two drinks) effect (within-subject), the effect-time interaction, and between-subject effects (ethnicity, gender, BMI categories) on blood glucose concentrations (five time-points). Continuous variables (e.g., 25(OH)D etc.) between groups are analyzed by two-way ANOVA. Dietary vitD intake between groups will be analyzed by one-way ANOVA (three groups) or independent t-test (two groups) should data are normally distributed otherwise Mann-Whitney test will be used. Categorical variables e.g. the percentage of vitD deficiency are compared by Chi-Square between groups. Data normality will be tested by Kolmogorov-Smirnov test. The generalized linear mixed models (GLMMs) for longitudinal data will also be used for modelling glycaemic response over time because this model accounts for the correlation between observations within each individual and adjusts confounding factors (e.g. BMI, age). The statistical significance will be reported with a p-value and a 95% confidence interval at a 5% significance level. The statistical software International Business Machines (IBM) SPSS 29 will be used to analyze data. Regression imputation will be used to deal with missing data. Both Intention-to-treat analysis and per protocol analysis will be used for the data analysis.

02

Conditions studied

  • Hyperglycemia, Postprandial
  • Vitamin D Status

Browse trials for

Keywords

  • Postprandial glycaemic response
  • Vitamin D
  • 25(OH)D
  • Ethnic groups
03

In context

Hyperglycemia

800 studies on the registry are indexed under Hyperglycemia; 115 are open to participants now.

This study's enrollment of 111 is above the median of 50 across 620 interventional studies indexed under Hyperglycemia.

Browse Hyperglycemia studies →

Lead sponsor

City, University of London is the lead sponsor of 25 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years
  • Live in any London Borough
  • Participants ethnicity is either White Caucasian, South Asian, or Black African-Caribbean

Exclusion criteria

Exclusion Criteria:

  • Mixed or multiple ethnicities
  • Diagnosis of diabetes
  • Diagnosis of a digestive system diseases
  • Diagnosis of a liver or kidney disease
  • Diagnosis of any other chronic diseases
  • Diagnosis of any blood clotting disorders
  • Are currently pregnant or breastfeeding
  • A (BMI) \<18.5 kg/m2
  • Consume alcohol more than 14 units per week
  • Regular smoker (one or more cigarettes per day)
  • On special diet
  • Gluten sensitivity or celiac disease
  • Fasting blood glucose ≥ 11 mmol/L
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Other
    White Caucasian group

    Participants from white Caucasian origin

    Other: Glucose drink · Other: Pure orange juice

  • Other
    South Asian group

    Participants from South Asian origin

    Other: Glucose drink · Other: Pure orange juice

  • Other
    Black African-Caribbean

    Participants from Black African-Caribbean origin

    Other: Glucose drink · Other: Pure orange juice

Interventions

  • OtherGlucose drink

    75g glucose in 300 ml water (281 kcal) used for oral glucose tolerance test (OGTT)

  • OtherPure orange juice

    300ml pure orange juice (OJ, Tesco 100% Pure Squeezed Orange Juice Smooth containing 129 kcal, 30 g sugar, 0.3 g fibre, 1.8 g protein and 90 mg vitamin C) from Tesco supermarket

06

What researchers measure

Primary outcomes

  1. Postprandial glycaemic response

    Blood glucose concentrations measured using HemoCue glucose analyser (HemoCue Ltd, Angelholm, Sweden) at five time points for each beverage (one visit per beverage)

    Time frame: Measured at fasted baseline (0 min), +30, +60, +90 and +120 minutes for each beverage

Secondary outcomes

  1. Plasma 25(OH)D

    Indicator of vitamin D status

    Time frame: Measured fasted at baseline (0 min) only

  2. Dietary vitamin D intake

    An estimated four-day food diary will be analyzed by using Nutritics software (Nutritics Ltd., Dublin).

    Time frame: Four consecutive days recorded between visits 1 and 2 (average 7 days)

  3. Knowledge and perception of vitamin D

    Participants will complete a seven question questionnaire via Qualtrics survey platform adapted from Boland et al 2015 - A Survey of University Students' Vitamin D-Related Knowledge. All questions are weighted evenly, resulting in a maximum of 7 points. A higher score indicates a greater level of Vitamin D knowledge.

    Time frame: Measured fasted at baseline (0 min) only

Other outcomes

  1. Participant body fat percentage

    body fat percentage will be measured using a bioelectric impedance analyzer (BIA) a TANITA DC 360 P (Tanita, Amsterdam). Height will be measured using stadiometer and entered into the BIA in order to calculate the body fat percentage. Weight is also recorded during this process, but is not used as an outcome measure.

    Time frame: Measured fasted at baseline (0 min) only

  2. Participant body mass index (BMI)

    BMI will be calculated from measured height in meters (using a stadiometer) and weight in kilograms (measured using a TANITA DC 360 P scale (Tanita, Amsterdam) using the formula: weight/(height\*height) and reported in kg/m-2

    Time frame: Measured fasted at baseline (0 min) only

  3. Plasma parathyroid hormone (PTH)

    Venepuncture blood sample collected, analyzed and reported in pg/mL

    Time frame: Measured fasted at baseline (0 min) only

  4. Plasma calcium

    Venepuncture blood sample collected, analyzed and reported in mmol/L

    Time frame: Measured fasted at baseline (0 min) only

  5. Total cholesterol

    Venepuncture blood sample collected, analyzed and reported in mmol/L

    Time frame: Measured fasted at baseline (0 min) only

  6. High-density lipoprotein (HDL)

    Venepuncture blood sample collected, analyzed and reported in mmol/L

    Time frame: Measured fasted at baseline (0 min) only

  7. Triglycerides (TG)

    Venepuncture blood sample collected, analyzed and reported in mmol/L

    Time frame: Measured fasted at baseline (0 min) only

  8. C-reactive protein (CRP)

    Venepuncture blood sample collected, analyzed and reported in mg/L

    Time frame: Measured fasted at baseline (0 min) only

07

Study locations

1 site
  • City, University of London
    London, N1 4FE, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06241976
Lead sponsor
City, University of London
Responsible party
Honglin Dong (Senior Lecturer, City, University of London) — Principal investigator
First posted
Feb 5, 2024
Start date
Jul 1, 2023
Primary completion
Feb 28, 2025
Completion
Feb 28, 2025
Last update
Mar 12, 2025

Study contacts

Honglin Dong
principal investigator · City, University of London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion